200 related articles for article (PubMed ID: 34455585)
21. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
Cyrenne BM; Lewis JM; Weed JG; Carlson KR; Mirza FN; Foss FM; Girardi M
Blood; 2017 Nov; 130(19):2073-2083. PubMed ID: 28972015
[TBL] [Abstract][Full Text] [Related]
22. Functional Depletion of HSP72 by siRNA and Quercetin Enhances Vorinostat-Induced Apoptosis in an HSP72-Overexpressing Cutaneous T-Cell Lymphoma Cell Line, Hut78.
Fujii K; Idogawa M; Suzuki N; Iwatsuki K; Kanekura T
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681913
[TBL] [Abstract][Full Text] [Related]
23. YKL-40 Promotes Proliferation of Cutaneous T-Cell Lymphoma Tumor Cells through Extracellular Signal-Regulated Kinase Pathways.
Suzuki H; Boki H; Kamijo H; Nakajima R; Oka T; Shishido-Takahashi N; Suga H; Sugaya M; Sato S; Miyagaki T
J Invest Dermatol; 2020 Apr; 140(4):860-868.e3. PubMed ID: 31622598
[TBL] [Abstract][Full Text] [Related]
24. Role of p38γ MAPK in regulation of EMT and cancer stem cells.
Xu M; Wang S; Wang Y; Wu H; Frank JA; Zhang Z; Luo J
Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3605-3617. PubMed ID: 30251680
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapeutic treatment is associated with Notch1 induction in cutaneous T-cell lymphoma.
Kamstrup MR; Biskup E; Manfè V; Savorani C; Liszewski W; Wirèn J; Specht L; Gniadecki R
Leuk Lymphoma; 2017 Jan; 58(1):171-178. PubMed ID: 27181628
[TBL] [Abstract][Full Text] [Related]
26. p38γ mitogen-activated protein kinase contributes to oncogenic properties maintenance and resistance to poly (ADP-ribose)-polymerase-1 inhibition in breast cancer.
Meng F; Zhang H; Liu G; Kreike B; Chen W; Sethi S; Miller FR; Wu G
Neoplasia; 2011 May; 13(5):472-82. PubMed ID: 21532888
[TBL] [Abstract][Full Text] [Related]
27. Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside.
Damsky WE; Choi J
Curr Treat Options Oncol; 2016 Jul; 17(7):33. PubMed ID: 27262707
[TBL] [Abstract][Full Text] [Related]
28. p38γ MAPK Inflammatory and Metabolic Signaling in Physiology and Disease.
Qi XM; Chen G
Cells; 2023 Jun; 12(13):. PubMed ID: 37443708
[TBL] [Abstract][Full Text] [Related]
29. Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma.
Kamijo H; Miyagaki T; Shishido-Takahashi N; Nakajima R; Oka T; Suga H; Sugaya M; Sato S
Blood; 2018 Nov; 132(18):1922-1935. PubMed ID: 30194255
[TBL] [Abstract][Full Text] [Related]
30. Loss of nuclear pro-IL-16 facilitates cell cycle progression in human cutaneous T cell lymphoma.
Curiel-Lewandrowski C; Yamasaki H; Si CP; Jin X; Zhang Y; Richmond J; Tuzova M; Wilson K; Sullivan B; Jones D; Ryzhenko N; Little F; Kupper TS; Center DM; Cruikshank WW
J Clin Invest; 2011 Dec; 121(12):4838-49. PubMed ID: 22080865
[TBL] [Abstract][Full Text] [Related]
31. miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.
Xia L; Wu L; Xia H; Bao J; Li Q; Chen X; Xia R
Cell Cycle; 2019 Jul; 18(14):1635-1645. PubMed ID: 31213131
[TBL] [Abstract][Full Text] [Related]
32. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Kamata M; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Clin Cancer Res; 2011 Dec; 17(24):7529-38. PubMed ID: 22048239
[TBL] [Abstract][Full Text] [Related]
33. Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma.
Sibbesen NA; Kopp KL; Litvinov IV; Jønson L; Willerslev-Olsen A; Fredholm S; Petersen DL; Nastasi C; Krejsgaard T; Lindahl LM; Gniadecki R; Mongan NP; Sasseville D; Wasik MA; Iversen L; Bonefeld CM; Geisler C; Woetmann A; Odum N
Oncotarget; 2015 Aug; 6(24):20555-69. PubMed ID: 26244872
[TBL] [Abstract][Full Text] [Related]
34. STAT5 induces miR-21 expression in cutaneous T cell lymphoma.
Lindahl LM; Fredholm S; Joseph C; Nielsen BS; Jønson L; Willerslev-Olsen A; Gluud M; Blümel E; Petersen DL; Sibbesen N; Hu T; Nastasi C; Krejsgaard T; Jæhger D; Persson JL; Mongan N; Wasik MA; Litvinov IV; Sasseville D; Koralov SB; Bonefeld CM; Geisler C; Woetmann A; Ralfkiaer E; Iversen L; Odum N
Oncotarget; 2016 Jul; 7(29):45730-45744. PubMed ID: 27329723
[TBL] [Abstract][Full Text] [Related]
35. The retinoid derivant ECPIRM selectively exhibited anti-proliferation effects in cutaneous T-Cell lymphoma via ITK-mediated signaling pathway.
Li H; Wang C; Ma P; Zhang M; Yang H; Yuan S; Wei J; Tao L; Qian K; Xu M; Li L
J Dermatol Sci; 2020 Mar; 97(3):208-215. PubMed ID: 32165081
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.
Chang TP; Poltoratsky V; Vancurova I
J Immunol; 2015 Mar; 194(6):2942-53. PubMed ID: 25681335
[TBL] [Abstract][Full Text] [Related]
37. p38γ and p38δ Are Involved in T Lymphocyte Development.
Risco A; Martin-Serrano MA; Barber DF; Cuenda A
Front Immunol; 2018; 9():65. PubMed ID: 29434594
[TBL] [Abstract][Full Text] [Related]
38. Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells.
Marzec M; Halasa K; Kasprzycka M; Wysocka M; Liu X; Tobias JW; Baldwin D; Zhang Q; Odum N; Rook AH; Wasik MA
Cancer Res; 2008 Feb; 68(4):1083-91. PubMed ID: 18281483
[TBL] [Abstract][Full Text] [Related]
39. Insights Into the Molecular and Cellular Underpinnings of Cutaneous T Cell Lymphoma.
Yumeen S; Girardi M
Yale J Biol Med; 2020 Mar; 93(1):111-121. PubMed ID: 32226341
[TBL] [Abstract][Full Text] [Related]
40. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
